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Abstract: The rough endoplasmic reticulum (ER) of nucleated human cells has crucial functions in
protein biogenesis, calcium (Ca2+) homeostasis, and signal transduction. Among the roughly one
hundred components, which are involved in protein import and protein folding or assembly, two
components stand out: The Sec61 complex and BiP. The Sec61 complex in the ER membrane represents
the major entry point for precursor polypeptides into the membrane or lumen of the ER and provides
a conduit for Ca2+ ions from the ER lumen to the cytosol. The second component, the Hsp70-type
molecular chaperone immunoglobulin heavy chain binding protein, short BiP, plays central roles
in protein folding and assembly (hence its name), protein import, cellular Ca2+ homeostasis, and
various intracellular signal transduction pathways. For the purpose of this review, we focus on
these two components, their relevant allosteric effectors and on the question of how their respective
functional cycles are linked in order to reconcile the apparently contradictory features of the ER
membrane, selective permeability for precursor polypeptides, and impermeability for Ca2+. The
key issues are that the Sec61 complex exists in two conformations: An open and a closed state
that are in a dynamic equilibrium with each other, and that BiP contributes to its gating in both
directions in cooperation with different co-chaperones. While the open Sec61 complex forms an
aqueous polypeptide-conducting- and transiently Ca2+-permeable channel, the closed complex
is impermeable even to Ca2+. Therefore, we discuss the human hereditary and tumor diseases
that are linked to Sec61 channel gating, termed Sec61-channelopathies, as disturbances of selective
polypeptide-impermeability and/or aberrant Ca2+-permeability.
Keywords: BiP; common variable immunodeficiency; congenital disorder of glycosylation; en-
doplasmic reticulum; neutropenia; polycystic liver disease; Sec61-channelopathies; Sec62; Sec63;
SSR/TRAP complex
1. Introduction
The ribosome-studded or rough endoplasmic reticulum (ER) of nucleated human
cells plays essential roles in protein biogenesis, calcium (Ca2+) homeostasis, and signal
transduction (Figure 1) [1–17]. Approximately one hundred ER proteins are involved
in two aspects of protein biogenesis at the ER, protein import and protein folding or
assembly (Table 1). Additional ER proteins are involved in (i) structurally shaping ER
sub-domains [18–22], (ii) vesicular transport for the delivery of native non-ER proteins to
other organelles with a function in endo- or exocytosis [23–25], (iii) ER-associated protein
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degradation (ERAD) [26–30] or ER-phagy [31–34], (iv) signal transduction pathways in
response to unfolded proteins (UPR) or the ER-stress induced pathway of apoptosis [35–40],
and (v) channels, receptors and pumps, which facilitate the controlled exchange of Ca2+
between the ER and other intra- and extracellular compartments [4,7–9,14–17,41–44]. Pro-
teins that need to be named in these respects are, for example, atlastins and reticulons for
ER morphology (i) [18–22], SNARE proteins, and small GTPases for vesicular transport
(ii) [25], Hrd1—and possibly Sec61 complex—together with the ATPase valosin-containing
protein or VASP for ERAD [26–30,45] and FAM134B -and possibly Sec62- for ER-phagy
(iii) [31,32]. IRE1, ATF6 and PERK for UPR and cytosolic CHOP are relevant for apoptosis
(iv) [35–40], and inositol-1,4,5-triphosphate receptor (IP3R), sarcoplasmic/endoplasmic
reticulum ATPase (SERCA), STIM plus ORAI and Sigma-1-receptor for Ca2+ homeostasis
(v) [4–17,46]. In relation to Ca2+ it is noteworthy that there is also un-controlled or passive
Ca2+-efflux from the ER, which has also been termed Ca2+-leakage, was recently linked
to ATP/ADP exchange across the ER membrane and may contribute to apoptosis when a
cell is sacrificed in order to save the organism [4–11,41–44]. Some of the proteins named
here will come up below or will be discussed in further detail in other articles of this
Special Issue.
Table 1. Protein transport components/complexes and associated proteins in HeLa cells.










- SRP72 355 Aplasia, Myelodysplasia
- SRP68 197










- hSnd2 (TMEM208) 81
- hSnd3 49
#Bag6 complex C
- TRC35 (Get4) 171
- Ubl4A 177
- Bag6 (Bat3) 133
SGTA 549 C
TRC40 (Asna1, Get3) 381 C
TA receptor ERM
- CAML (CAMLG, Get2) 5
- WRB (CHD5, Get1) 4 Congenital Heart Disease
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Table 1. Cont.
Component/subunit Abundance Location Linked Diseases





- EMC5 (MMGT1) 35






- TMCO1 ## 2013 Glaucoma, Cerebrofaciothoracic Dysplasia
- Nicalin 99
- TMEM147 21




- CCDC47 (Calumin) 193
PEX19 80 C Zellweger Syndrome
PEX3 103 ERM Zellweger Syndrome
#Sec61 complex ## ERM
- Sec61α1 139 Diabetes **, CVID, TKD, Neutropenia
- Sec61β 456 PLD, Colorectal Cancer
- Sec61γ 400 GBM, Hepatocellular Carcinoma, RCC
#Sec62 (TLOC1) 26 ERM Breast-, Prostate-, Cervix-, Lung-Cancer et al.
ER Chaperones
Sec63 (ERj2) 168 ERM PLD, Colorectal Cancer et al.
#ERj1 (DNAJC1) 8 ERM
ERj3 (DNAJB11) 1001 ERL Polycystic Kidney Disease (PKD)
ERj4 (DNAJB9) 12 ERL
ERj5 (DNAJC10) 43 ERL
ERj6 (DNAJC3, p58IPK) 237 ERL Diabetes, Neurodegeneration
ERj7 (DNAJC25) 10 ERM Hyperinsulinismus, Allergic Asthma
ERj8 (DNAJC16) 24 ERM
ERj9 (DNAJC22) ERM
BiP (Grp78, HSPA5) 8253 ERL Hemolytic Uremic Syndrome (HUS)
Grp170 (HYOU1) 923 ERL Immunodeficincy & Hypoglycemia
Sil1 (BAP) 149 ERL Marinesco-Sjögren-Syndrome (MSS)
Grp94 (CaBP4, Hsp90B1) 4141 ERL
PPIB (Cyclophilin B) 1289 ERL
FKBP2 (FKBP13) 894 ERL
PDIA1 (PDI, ERp59) 3624 ERL Cole-Carpenter Syndrome
PDIA2 (PDIp) ERL
PDIA3 (ERp61, Grp57) 3730 ERL
PDIA4 (ERp72, CaBP2) 2173 ERL
PDIA5 (PDIR) 37 ERL
PDIA6 (P5, CaBP1) 3001 ERL
PDIA9 (ERp29) ERL
Calreticulin (CaBP3, ERp60) 14521 ERL
#Calnexinpalmitoylated 7278 ERM
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Table 1. Cont.




- TRAPα (SSR1) 568
- TRAPβ (SSR2)
- TRAPγ (SSR3) 1701 CDG, Hepatocellular Carcinoma
- TRAPδ (SSR4) 3212 CDG
#RAMP4 (SERP1) ERM
#Oligosaccharyltransferase (OST-A) ERM
- RibophorinI (Rpn1) 1956
- RibophorinII (Rpn2) 527








- RibophorinI (Rpn1) 1956
- RibophorinII (Rpn2) 527




- Stt3B* 150 CDG
- TUSC3 CDG
- MagT1 33
Signal peptidase (SPC-A) ERM
- SPC12 2733
- SPC18 * (SEC11A)
- SPC22/23 334
- SPC25 94
Signal peptidase (SPC-C) ERM
- SPC12 2733
- SPC21 * (SEC11C)
- SPC22/23 334
- SPC25 94







ALG8 10 ERM CDG, PLD
UGGT 232 ERL
Glucosidase IIα (GIIα) ERL PLD
Glucosidase IIβ (PRKCSH, GIIβ) ERL PLD
Proly-4-hydroxylase α (4-PH) ERL
Proly-4-hydroxylase β (PDI) 3624 ERL Cole-Carpenter Syndrome
SUMF1 23 ERL Multiple Sulfatase Deficiency
SUMF2 386 ERL Multiple Sulfatase Deficiency
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Table 1. Cont.
Component/subunit Abundance Location Linked Diseases
#p34 (LRC59, LRRC59) 2480 ERM
#p180 (RRBP1) 135 ERM Hepatocellular Carcinoma, Colorectal Cancer
Kinectin 1 (KTN1) 263 ERM
Protein classes or complexes are characterized by italics, subunits of complexes are identified by hyphens, alternative names of components
or subunits are given in parentheses. Abundance is given in nM according to Hein et al. (see Data Availability) C, cytosol; CDG, Congenital
disorder of glycosylation; CVID, Common variable immunodeficiency; ERL, ER lumen; ERM, ER membrane; GBM, Glioblastoma
multiforme; PLD, polycystic liver disease; RCC, renal cell carcinoma; SUMF, sulfatase modifying factor or formylglycine generating
enzyme; TKD, Tubulo-interstitial kidney disease; UGGT, UDP-glucose-glycoprotein glucosyltransferease. *, catalytically active; **, in mice;
#, ribosome associated; ##, ion channel activity. We note that (i) Calnexin, ERj1, ERp72, P5, Sec61β, Sec63, SRα, TRAM1, and TRAPα
were shown to be subject to phosphorylation, (ii) BiP, Calnexin, Calreticulin, CCDC47, Grp94, Sec62 and TRAPα are calcium binding
proteins, (iii) Sec63, TRAPα, and TRAPβ were predicted to comprise immunoglobulin-like β sandwich domains in the cytosol and ER
lumen, respectively, (iv) hSND3, WRB, EMC3, TMCO1, Sec62, Sec63, and ERj1 were predicted to comprise cytosolic coiled coil domains,
and (v) WRB, EMC3, and TMCO1 are OXA1-homologs.
The heterotrimeric Sec61 complex of the ER membrane represents the major entry point
for precursor polypeptides into the membrane or lumen of the ER (Figures 1 and 2) [47–59].
Therefore, it can form an aqueous polypeptide-conducting channel, which also allows the
passage of Ca2+ in the opposite direction [60–69]. The channel exists in two conformations,
an open and a closed state that are in a dynamic equilibrium with each other (Figure 2). The
closed conformation is impermeable even to Ca2+. Thus, the Sec61 complex is a precursor-
gated channel, which operates either coupled to translation (in co-translational transport)
or after completion of translation (in post-translational transport). Sec61 gating to the open
state is not solely facilitated by its substrates, the amino-terminal signal peptides (SPs) or
transmembrane helices (TMHs) of precursor polypeptides [70–75], it is also supported by
ribosomes in co-translational transport [52,55] and/or by several Sec61 interaction partners,
such as translocon-associated protein or TRAP complex [53,56,76,77] and Sec62/Sec63
complex in cooperation with BiP [69,78–81], respectively. Here, the latter are defined as
allosteric effectors of the channel since they interact with the complex at sites, which are
distinct from the precursor binding sites. Channel closing also appears to be facilitated by
allosteric effectors, such as the ER-lumenal BiP [69] and/or the cytosolic Ca2+-calmodulin
(CaM) [68]. In our opinion, Sec61 channel gating can best be described in analogy to
an enzyme-catalyzed reaction (Figure 3): Channel opening and closing represent two
energetically un-favorable reversible reactions and the substrates and effectors are the
catalysts, which lower the activation energy for the required conformational transitions by
binding to the Sec61 complex [57,58].
The Hsp70-type molecular chaperone immunoglobulin heavy chain binding protein
or BiP [82] does not only support Sec61 channel opening for ER protein import [69,78],
but also can bind to incoming precursor polypeptides and act on these as a molecular
ratchet [83]. Thus, typical for an Hsp70, the ATP- and Ca2+-dependent BiP modulates the
conformation of a folded protein complex, the Sec61 channel, plus interacts with a more or
less unfolded polypeptide chain as it emerges from the Sec61 channel, thereby contributing
to a unidirectional or irreversible transport process. Also typical for an Hsp70, both BiP
activities involve an ATPase cycle and their own allosteric effectors, i.e., J-domain-proteins
(JDPs) [84] or Hsp40-type co-chaperones, termed ERj- or ERdj-proteins, and nucleotide
exchange factors (NEFs). Following the same principles and interactions, BiP also plays
a central role in folding and assembly of newly-imported polypeptides, such as heavy
and light chains of immunoglobulins in the plasma cells of the immune system [85], and
supports efficient Sec61 channel closing to preserve Ca2+ homeostasis [69]. In addition, BiP
is a key player in various Ca2+-dependent and -independent signal transduction pathways,
which report on ER energy- and protein-homeostasis (proteostasis), as reviewed in other
articles of this Special Issue.
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Figure 1. Collage of 3D reconstructions of a nucleated mammalian cell, a section of rough ER in such a cell and a ribosome-
bound Sec61 translocon. (a) Represents a 3D reconstruction after live cell fluorescence imaging, following import of GFP
into the ER and of RFP into the mitochondria. The plasma membrane is indicated by a dashed line. Typical concentrations
of free Ca2+ are given for cytosol and ER of a resting cell. (b) depicts a 3D reconstruction of cellular rough ER after CET of a
slice through the respective tomogram. ER membranes are shown in yellow; 80S ribosomes are shown in blue. (c) represents
a 3D reconstruction of the native ribosome-translocon complex in rough microsomes. Here, the membrane density was
removed to highlight membrane integral parts of the translocon complex. TMHs for Sec61 complex, TRAP and OST can
be distinguished [56]. Helix 51 of an rRNA expansion segment and ribosomal protein eL38 represent the contact sites of
TRAPγ, but are hidden by other ribosomal densities. (d) shows the PDB 3j7q structures for the Sec61 channel as seen from
the indicated positions; disease associated point mutations are indicated. The collage is based on [57,58]. See text for details.
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Figure 2. The concept of gating of the heterotrimeric Sec61 complex by signal peptides and allosteric effectors. The Sec61
channel is shown in its modeled closed (top) and open (bottom) conformational states, as viewed from the plane of the
membrane (left) and in atomic models (PDB 3j7q, PDB 3jc2) as seen from the cytosol (right), respectively [57,58]. These
two states are proposed to be in a dynamic equilibrium with each other. The fully open state of the Sec61 channel allows
the initial entry of precursor polypeptides from the cytosol into the ER lumen and ER membrane, respectively, and is
experimentally observed as cleavage of signal peptides by signal peptidase on the luminal side of the ER membrane. In
addition, it allows the passive efflux of Ca2+ from the ER lumen into the cytosol and is visible in live cell Ca2+ imaging in
cytosol and ER lumen. Ca2+ efflux may also be possible in the expected transition state (not shown), which may be identical
to the so-called primed state that can be induced by ribosomes in co-translational- and by the Sec62/Sec63 complex in
post-translational-transport. The conformational changes of the modelled Sec61 complex were previously morphed and the
role of BiP plus an ERj co-chaperone, such as Sec63 and ERj1, respectively, visualized for co-translational transport at (see
Data Availability). The Ca2+-permeability of the open Sec61 channel as observed by live cell Ca2+ imaging can be seen in
the video file (see Data Availability).
In this article, we zoom in on the question of how the functional cycles of BiP and
the Sec61 channel are intertwined and which allosteric effectors of the two are involved in
these reactions. Furthermore, we discuss the human hereditary and tumor diseases as well
as human pathogens that are linked to Sec61 channel gating, the Sec61-channelopathies, as
disturbances of selective polypeptide-impermeability and/or Ca2+ permeability of the ER
membrane and highlight the importance of the functionality of the system [86].
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Figure 3. Energetics and kinetics of Sec61 channel gating. In our view, the TRAP− or Sec62/Sec63 +/− BiP-mediated
Sec61 channel gating is best considered in analogy to an enzyme-catalysed reaction. Accordingly, TRAP, Sec62, Sec63 or
BiP reduce the energetic barrier for full channel opening, which can apparently be reinforced by Sec61 channel inhibitors,
such as cyclic heptadepsipeptides (such as CAM741) or certain eeyarestatins (such as ES24). At least in the case of ES24,
binding of the inhibitor within the channel pore arrests the channel in a partially open state (termed “foot in the door”),
which maybe identical with the primed state and is compatible with Ca2+-efflux but not with full channel opening for
protein translocation. TRAP and BiP contribute to full channel opening by direct interaction with ER luminal loops 5 and 7,
respectively, of Sec61α (see below). SEC61A1 mutations can increase the energy barrier for channel opening per se (V67G,
V85D, and Q92R mutation) or indirectly, such as by interfering with BiP binding (Y344H mutation). Notably, all these effects
are precursor specific because the amino-terminal SPs are either efficient or inefficient in driving Sec61 channel opening.
Typical for an enzyme-catalysed reaction, BiP can also support efficient gating of the Sec61 channel to the closed state, i.e.,
the reverse reaction.
2. The Human Sec61 Translocon
Protein import into the ER is the first step in the biogenesis of precursors of about
10,000 different soluble and membrane proteins of nucleated human cells, which amounts
to about 30% of the proteome [1–3]. All these proteins fulfill their functions either in the
membrane or lumen of the ER (plus the connected nuclear envelope), in one of the or-
ganelles of the pathways for endo- and exocytosis (i.e., ERGIC, Golgi apparatus, endosome,
lysosome), in lipid droplets or at the cell surface as plasma membrane- or secretory-proteins.
ER protein import involves the two stages of membrane targeting and insertion of nascent
membrane proteins into or translocation of soluble precursor polypeptides across the ER
membrane. Typically, both processes depend on SPs or TMHs at the amino-termini of the
precursor polypeptides [70–75]. In general, these SPs have a tripartite structure. They com-
prise a more or less positively charged amino-terminal or N-region, a central hydrophobic
or H-region and a slightly polar carboxy-terminal or C-region (Figure 4). Other than that,
they do not have sequence homologies and, as a matter of fact, show quite some variability
with respect to length (15–50 amino acid residues) as well as overall properties (see below).
Interestingly, various human hereditary diseases are the result of single point mutations in
the SPs of certain precursor polypeptides (such as preproinsulin and preprorenin), which
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result in failure of these SPs to deliver their otherwise functional mature forms to the correct
cellular location, thus, highlighting the fact that these amino-terminal SPs were fine-tuned
to their respective receptors by evolution [87–89]. In addition, insertion of SPs may occur
co- or post-translationally and are facilitated by various pathways and components, which
reside in the cytosol and the ER membrane or lumen, respectively (Table 1).
Figure 4. Features of amino-terminal signal peptides and ER membrane proteins. The cartoon depicts the signal peptides
(SPs, shown in yellow) and six types of ER membrane proteins (in black), together with their membrane protein type and
mechanism of membrane insertion (both indicated below the cartoon). Cleavable SPs (in yellow) can facilitate ER import of
secretory proteins (in green), glycosylphosphatidylinositol (GPI)-anchored membrane proteins (in green) and various types
of membrane proteins, except for hairpin-, type II- and tail anchored-membrane proteins. Positively charged amino acid
residues (+) play an important role in membrane protein and SP orientation, i.e. typically, follow the positive inside rule.
Bitopic and polytopic proteins can also involve SPs and have the opposite instead of the shown orientation. Alternatively,
amino-terminal transmembrane helices (TMHs), which serve as SPs, facilitate membrane insertion. The shown bitopic
protein is also named double-spanning membrane protein, the example polytopic protein is also named tetra-spanning
membrane protein, if the shown type I membrane protein did not involve a cleavable SP it is also defined as signal anchor
protein. In the case of membrane proteins with amino-terminal TMHs, membrane insertion typically involves the same
components and mechanisms, which deliver secretory proteins (in green) and glycosylphosphatidylinositol (GPI)-anchored
membrane proteins (in green) to the ER lumen. In certain cases, however, auxiliary membrane protein insertases, such
as EMC or TMCO1 complex play a role. The latter two membrane protein complexes can also operate as stand-alone
membrane protein insertases, an activity they have in common with the PEX- and the TRC-systems. Following their ER
import, GPI-anchored membrane proteins become membrane anchored via their carboxy-termini by GPI-attachment. C,
carboxy-terminus; N, amino-terminus.
2.1. Entry of Precursor Polypeptides into the ER
The heterotrimeric Sec61 complex of the ER membrane represents the entry point
for most precursor polypeptides with a SP or TMH into the membrane or lumen of the
ER (Figures 1–3) [48–50]. Cryo-electron tomography (CET) of cells or isolated ER-derived
vesicles (rough microsomes) depicts the Sec61 as a large multicomponent assembly in
association with translating ribosomes and the membrane-embedded TRAP (also termed
SSR) complex and oligosaccharyltransferase (OST), the enzyme complex that catalyzes
N-linked glycosylation (Figure 1c) [51,53,54,56]. This super-complex was termed Sec61
translocon and can insert into the membrane or fully import into the lumen an amazing
variety of precursor polypeptides (Figure 4). These precursors mature to (i) membrane
proteins with one, two or multiple TMHs and with their amino-termini either in the cytosol
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or the ER lumen, (ii) GPI-anchored membrane proteins or (iii) soluble proteins in the ER
lumen, such as secretory proteins. Membrane insertion is either mediated by a cleavable
amino-terminal SP or the amino-terminal TMH of the nascent precursor polypeptide.
The import of soluble polypeptides into the lumen is invariably mediated by cleavable
amino-terminal SPs. GPI-anchored membrane proteins are imported in analogy to soluble
polypeptides and, concomitantly, modified by another multimeric enzyme complex called
GPI transamidase. In this case, membrane integration is limited to the lipid moiety of the
GPI-anchor [90]. Cleavable SPs are removed from the inserting or incoming precursor
polypeptides by yet another heteromultimeric enzyme, the signal peptidase complex
(SPC) [91,92].
2.2. Targeting of Precursor Polypeptides to the ER
Prior to ER entry, however, precursor polypeptides have to be targeted to the ER
membrane [93]. In case of the Sec61-dependent ER import, co-translational ER targeting
is mediated by the cytosolic ribonucleoparticle signal recognition particle (SRP) and its
heterodimeric receptor in the ER membrane, termed SRP receptor or SR (Table 1) [94–98].
Another binary targeting system consisting of a single ribosome-associating component
(SND1) and a heterodimeric membrane receptor (SND2 plus SND3) directing precursor
polypeptides to the Sec61 complex was identified in yeast and named SRP-independent
(SND) pathway [99–104]. In human cells only SND2 was found to be conserved compared
to yeast and the other components still await identification. In human cells this targeting
pathway can for example be used by small presecretory proteins (i.e., precursors with less
than 100 amino acid residues, such as preproapelin and prestatherin) [102,103]. Thus, for
posttranslational import of small precursor proteins via the Sec61 complex, ER targeting can
occur via the SND pathway or via direct contact with the Sec61 complex and its associated
components (Sec62). In addition to the above-mentioned membrane proteins, the ER
membrane also contains hairpin- and tail-anchored or TA-membrane proteins, which
depend on dedicated components and post-translational pathways for their membrane
insertion (Figure 4). The TRC-pathway (GET-pathway in yeast) handles TA proteins and
the PEX3-dependent pathway at least one hairpin protein, which is destined to lipid
droplets [105–116]. In case of the TRC- and PEX-pathways, targeting to these membrane
components is mediated by the Bag6 complex plus additional cytosolic factors and PEX19,
respectively. For reasons of clarity, this article will more or less ignore the latter two
pathways and, instead, focus on Sec61-dependent import.
Notably, however, one general lesson from the analysis of these pathways is that
they are not strictly separated from each other and that there are at least some precursor
polypeptides, which can be handled by more than one pathway. Some small human
presecretory proteins (such as preproapelin), for example, can be targeted to the Sec61
complex via the SRP-, SND-, and TRC-pathway or directly via Sec62 [102]. Furthermore,
at least some TA-membrane proteins (such as Sec61β and RAMP4) can be targeted to
the membrane via the same three pathways as small presecretory proteins [100]. Thus,
there is redundancy in these three targeting systems and they can substitute for each
other as a backup at least to a certain extent. Another general lesson is that not all amino-
terminal SPs and TMHs, which are involved in ER targeting and import of precursor
polypeptides, were created equal, i.e., some have special requirements, which is not
surprising considering the large variety of precursor polypeptides (Figure 4). This is
where allosteric effectors of the Sec61 complex (BiP together with Sec62/Sec63 complex
or TRAP complex) (Figures 2 and 5) and auxiliary membrane protein insertases (EMC
and TMCO1 complex) join the game [117–126]. In order to insert into the membrane or
import such a large variety of different precursor polypeptides, the Sec61 complex can
form a relatively promiscuous and wide aqueous polypeptide-conducting channel, which
is supported by its overall structural design and described next.
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2.3. Structure of the Sec61 Complex
The structure of the human Sec61 complex was first deduced from the X-ray crystal-
lographic analysis of the ortholog archaean SecY complex by T. Rapoport and colleagues
(Figure 1d) [127]. The high sequence conservation of the SecY and Sec61 subunits in-
dicated that their architecture and dynamics are evolutionarily conserved, which was
since confirmed by various subsequent cryo-electron microscopy—(cryo-EM)— studies on
detergent-solubilized or reconstituted ribosome-bound SecY or Sec61 complexes. Accord-
ingly, the central polypeptide-conducting channel forming subunit (Sec61α − or correctly
Sec61α 1 because there also is an uncharacterized Sec61α 2 coded by the human genome)
comprises ten TMHs, which are connected by four cytosolic plus five ER lumenal loops
(Figure 5). The complex is arranged in pseudo-symmetrical amino- and carboxy-terminal
halves with an overall hourglass-shaped structure and a central constriction. This constric-
tion is called pore ring and is sealed by a ring of the bulky hydrophobic residues I81, V85,
I179, I183, I292 plus L449 in TMHs 2, 5, 7, and 10. A short, flexible helix between residues
F62 and S82 of the luminal loop 1 was termed plug helix. The two halves are connected
by a “hinge” region and subunits Sec61β and Sec61γ are located on the outskirts of the
Sec61 complex and comprise one tail anchor each. Strikingly, two distinct conformational
states of the Sec61 channel could be distinguished, which differ in the relative positioning
of the amino- and carboxy-terminal halves of Sec61α (Figure 2). These states either allow
or prevent lateral access of amino-terminal SPs or TMHs of precursor polypeptides from
the central pore into the lipid bilayer through the so-called lateral gate, which is formed by
TMHs 2 and 7 of Sec61α (Figures 1d and 2). Furthermore, they either do or do not connect
the cytosol and ER lumen via an aqueous channel formed by Sec61α.
Subsequent structural determination of programmed ribosome-Sec61 complexes sug-
gested a series of events upon arrival of a nascent precursor polypeptides [52,55]. Ac-
cordingly, in co-translational transport, the closed Sec61 complex is primed by binding
of the ribosome to cytosolic loops 6 and 8 of Sec61α as well as the amino-terminus of
Sec61γ, unveiling a hydrophobic patch in the cytosolic funnel formed by Sec61α, which
involves the residues V85, L89, I179 plus I293 from TMHs 2, 5 and 7, 5. This patch in
vicinity to the lateral gate serves as an interaction site for an incoming SP, more precisely,
the H-region within the SP of the precursor polypeptide. This hydrophobic interaction
supports the rigid body movement of the amino- and carboxy-terminal halves of Sec61α
and the channel becomes fully open with the pore ring widened and the plug displaced.
The open Sec61 channel than allows the precursor polypeptide axial access to the ER lumen
or lateral access into the membrane. The cryo-EM data as well as biochemical analyses also
demonstrated that even in co-translational translocation, a considerable stretch of certain
nascent precursor polypeptides can accumulate at the interface between the ribosome and
the Sec61 channel without necessarily aborting translocation [128]. This indicated that
nascent precursor polypeptide chain elongation does not or at least not always provide the
driving force for translocation.
CET of Sec61 translocons in rough microsomes derived from human cell lines and
even in intact cells has given further insight into the architecture and dynamics of the Sec61
channel in its physiological setting (Figure 1c) [53,54,56,129]. The atomic model of the
solubilized ribosome-bound Sec61 complex [52], opened laterally by SPs, was easily docked
into the CET density, defining the position and conformation of Sec61α in the center of the
native translocon. Furthermore, weak helical density in front of the lateral gate in the CET
density map confirmed the positioning of SPs observed after detergent solubilization of
ribosome-Sec61 complexes. The Sec61 channel was found in a laterally open conformation,
possibly implying that the Sec61 channel remains laterally open throughout the complete
process of protein translocation. However, at this point the aqueous pore in the center
of the channel can be expected to be occupied by the polypeptide chain in transit and,
therefore, impermeable to ions.
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Figure 5. Topology and functionally relevant domains of the heterotrimeric Sec61 complex and its allosteric effectors TRAP,
BiP, Sec62, and Sec63. The membrane topology of the three subunits of the mammalian Sec61 complex indicates binding
sites (termed BS) for the ribosome (R, cytosolic loops 6 and 8 of Sec61α) and the TRAP complex (loop 5 of Sec61α) in (a) and
for Ca2+-calmodulin (CaM, IQ) and BiP (loop 7 of Sec61α) in (b). The relevant allosteric effectors of BiP (ERjs and NEFs) are
also shown in (b), as are additional interaction partners of Sec62 (LC3) [32] and Sec63 (nucleoredoxin or NRX, calumenin or
Calu) [130]. Recent work demonstrated that IRE1a interacts with Sec61 and connects protein translocation and Ca2+ leakage
with UPR. Furthermore, functional domains (J-domain, NBD, SBD, TPR) plus motifs (IQ, EF hand) and disease-associated
mutations of Sec61α are indicated (in red; amino acid residues are given in single letter code). C, carboxy-terminus; N,
amino-terminus. Notably, recent 3D reconstructions after single particle cryo-electron microscopic analysis of the yeast
SEC complex showed that in the post-translationally acting Sec61 complex, the Sec62/Sec63 sub-complex interacts with the
cytosolic loops 6 and 8 on the cytosolic face of the Sec61 complex, and that the ER luminal domain of Sec63 interacts with
ER luminal loop 5 of Sec61α.
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2.4. Dynamics of the Sec61 Complex
Originally, the dynamics of the Sec61 channel were observed in single-channel record-
ings from planar lipid bilayers, which were derived from canine pancreatic rough micro-
somes, after artificial release of nascent precusor polypeptides from membrane bound
ribosomes by puromycin. This technique was introduced by S. Simon and G. Blobel in 1989
to the field [47], i.e., at a time where the Sec61 complex had not yet been discovered, and
suggested a pore of about 10 Angstrom. Almost fifteen years later and after the discovery of
the complex by T. Rapoport and R. Schekman, respectively, this approach was reproduced
and adapted to purified and reconstituted canine pancreatic Sec61 complexes [61]. The
complex was characterized as a highly dynamic aqueous pore with pore diameters ranging
from 12 to 22 Angstrom that is (i) initially opened by SPs of defined ribosome-nascent
precursor polypeptide chain-complexes (so-called RNCs) or fully-synthesized small prese-
cretory proteins, (ii) subsequently occupied and sealed by the polypeptide chain in transit,
(iii) transiently open upon release of the chain in transit and (iv) then closed, which allows
a new translocation cycle to begin. The open channel was found to be permeable to various
ions, including Ca2+, and even small molecules [67–69,131–133].
A priori and supported by these dynamic studies, the static structural analysis of
Sec61 complexes in different states and many in vitro studies on ER protein import, it
is clear that the opening of the precursor polypeptide-conducting Sec61 channel during
early steps of ER protein import is mediated by SPs and TMHs [134]. Typically, the latter
first approach the cytosolic funnel of the Sec61 channel [57,70,93,135]. Next, they start
sampling the cytosolic funnel of the Sec61 channel as brilliantly simulated and visualized
by Zhang and Miller [136] for co-translational transport. According to these simulations,
sampling in the Sec61 channel pore is affected by deleterious charges, hydrophobicity,
mature protein length, arrest peptides, or poly-proline motifs in the precursor polypeptides
and translation speed, which is dependent on pause sites, rare codons or hairpins in the
mRNA. For productive SP or TMH insertion into the Sec61 channel and concomitant
complete opening of the Sec61 channel, a high hydrophobicity, i.e., low ∆Gpred value for
the H-region were found to be conducive [135–137]. H-region hydrophobicity of the SP
or TMH is recognized by the hydrophobic patch in the Sec61α TMHs 2 and 7, which line
the lateral gate of the channel [127]. Typically, the SP- and TMH-orientation in the Sec61
channel follows the positive inside rule [138–140], i.e., positively charged residues in the
N-region support loop insertion (Ncytosol-CER-lumen), while positively charged side chains
downstream of the SP or TMH interfere with loop insertion and favour head-on insertion
(NER-lumen-Ccytosol), which can be followed by a so-called “flip turn” (Figure 4) [135,141].
For SPs with low overall hydrophobicity in combination with high glycine- plus proline-
content full Sec61 channel opening in co-translational transport is supported by the TRAP-
complex [142]. To accommodate SPs with low H-region hydrophobicity in combination
with detrimental features within the mature part, full Sec61 channel opening is supported
by the Sec62/Sec63-complex with or without BiP involvement in co- and post-translational
transport [102,143]. Notably, lower SP hydrophobicity has also been observed to be decisive
for Sec62p/Sec63p-involvement in post-translational ER protein import in yeast [144].
2.5. Auxiliary Factors of the Sec61 Complex
The first hints on participation of additional components in co-translational protein
transport came from the analysis of ribosome-associated ER membrane proteins present in
detergent extracts of canine pancreatic rough microsomes. The term ribosome-associated
membrane proteins (RAMPs) was coined for this class of membrane proteins after their
solubilization in the presence of high salt concentrations [48,49]. By definition, the Sec61
complex is a RAMP, and so are RAMP4, TRAP, and OST (Table 1). More recently, ERj1 and
Sec62 were characterized as RAMPs, although their ribosome association is seen only under
more physiological salt concentrations and therefore may be more dynamic compared
with the high-salt resistant RAMPs [145–148]. More information on the composition of the
native protein transport machinery in the ER membrane came from fluorescence resonance
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energy transfer experiments, which employed fluorescently labeled antibodies against
transport components, permeabilized MDCK cells, and fluorescence microscopy. Accord-
ing to this cell biological strategy, Sec61α1, Sec61β, Sec62, and ERj1 are RAMPs [147–149].
Furthermore, this approach demonstrated that SR, the TRAP complex, and translocat-
ing chain-associating membrane (TRAM) protein are permanent nearest neigbours of
Sec61 complexes. Additional cross-linking data suggested that SR and Sec62 interact with
Sec61α in a mutually exclusive manner and may use the same binding site at the cytosolic
amino-terminus [150].
2.5.1. Allosteric Effectors of the Sec61 Channel for Channel Opening
It is clear that some amino-terminal SPs or TMHs are strong enough to trigger immedi-
ate Sec61 channel opening on their own (such as the SP of bovine preprolactin), particularly
after the ribosome has already primed the channel. However, precursor polypeptides
with weak SPs involve auxiliary components in Sec61 channel opening and, therefore,
in facilitating insertion of precursor polypeptides into the Sec61 complex, such as the
ER-lumenal chaperone BiP together with the Sec62/Sec63 complex or the TRAP com-
plex (Table 1) [142,143]. Alternatively, the auxiliary components may support the above-
mentioned flip turn of the SP in case of an original erroneous head-first insertion. This view
is based on the observations in both the yeast and the mammalian system that these auxil-
iary components can facilitate the flip turn of TMHs, i.e., affect the topology of TMHs that
do not promote a specific initial orientation of membrane protein precursors in the mem-
brane or to mediate topology of moderately hydrophobic signal anchor proteins, e.g., in
particular type II membrane proteins that undergo the flip turn for reversing the initial type
I orientation [138,139,141,144,151,152]. Based on in vitro and in cellulo experiments the con-
cept emerged that TRAP and Sec63 plus BiP facilitate Sec61 channel opening in a substrate
specific manner [76–81]. By definition, precursor polypeptides with weak SPs or TMHs
were found to be affected by depletion of either component (Figure 5) [69,102,153–157].
Based on only a small set of model precursor polypeptides (such as preproapelin, pre-prion
protein, and pre-ERj3) and import into the ER of semi-permeabilzed or intact human cells,
the distinguishing factor that determines the requirement for BiP and Sec63 was suggested
to be a short and rather apolar signal peptide in combination with detrimental clusters of
positive charges in the mature part [102,129,156]. We suggest that the positively charged
side chains downstream of the SP interfere with loop insertion of the SP and, therefore,
increase the energetic barrier for Sec61 channel opening (Figure 3). The TRAP complex
was observed in similar in vitro transport studies to stimulate translocation of specific
proteins (such as the prion protein) indicating that there may also be redundancy at the
level of the allosteric Sec61 effectors in channel opening [76,77,153–156,158–161]. More
recently, the combination of siRNA mediated depletion of a certain transport component
from human cells with subsequent cellular protein abundance analysis characterized SPs
with comparatively longer but less hydrophobic H-regions and lower C-region polarity
as Sec62/Sec63 dependent and above-average glycine-plus-proline content and below-
average hydrophobicity of SPs as feature for TRAP dependence [142,143].
2.5.2. Additional Auxiliary Factors of the Sec61 Complex
As noted before, several additional proteins in the mammalian ER membrane also
can be considered as auxiliary components, apparently, without affecting Sec61 chan-
nel gating, most notably translocating chain-associated membrane protein or TRAM
(Table 1) [162–171]. In the case of TRAM, precursors with a long N-region as well as
long H-region of the SP showed a low TRAM dependence in in vitro experiments, which
was since supported by the above-mentioned in cellulo experiments. Interestingly, there
is a second TRAM in mammalian cells, termed TRAM2, which can invert the topology of
TMHs that do not promote a specific initial orientation in the membrane [172,173], which is
reminiscent of TRAP and Sec62/Sec63 (see above). We note that TRAM2 was characterized
as SERCA interaction partner, i.e., also has a connection to Ca2+-homeostasis. In contrast
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to Sec61, TRAP, and OST, TRAM was not identified by CET in native ER membranes,
which were derived form human cells after component depletion, probably because of its
almost complete membrane embedding. Nevertheless, it was suggested to represent the
density, which is consistently found opposite of the lateral gate of the Sec61 channel [51].
So far, TRAM function remains poorly defined. Based on its TLC domain, however, it was
proposed to affect bilayer thickness and/or phospholipid packing in the vicinity of the
lateral gate in order to support lateral exit of SPs and TMHs, in analogy to bacterial YidC
and mitochondrial Oxa1 [171,174,175].
However, notably, WRB (Get1 in yeast), EMC3 and TMCO1 are also considered as
YidC and Oxa1 homologs (Table 1) [124]. ER membrane protein complex (EMC) was first
identified in yeast and later in human cells as a heteromultimeric protein complex with six
and ten subunits, respectively. Biochemical and cellular characterization of the decameric
EMC characterized it as both stand-alone insertase for example for TA- membrane proteins
with a moderately hydrophobic transmembrane helix and as helper membrane protein
insertase in synergy with the Sec61 complex for the insertion of critical TMHs of polytopic
membrane proteins [117–121]. It was proposed to cause local membrane thinning. Besides
this stable decameric protein complex TMCO1 has been shown to be in contact with the
Sec61 complex and to facilitate membrane protein insertion (Table 1) [124,125]. In partial
analogy with YidC, TMCO1 was originally found in association with both ribosomes
and the Sec61 complex. Under these conditions, it forms a transient pentameric complex
with four additional subunits and functions as either stand-alone or auxiliary membrane
protein insertase to the Sec61 complex for TMHs with insufficient hydrophobicity. As
stated above, several small human precursor polypeptides were observed to translocate
post-translationally and ribosome-independently into the human ER. For a subset of them,
ER-targeting was reported to occur independently of SRP and SR and to alternatively
involve cytosolic TRC40 (Get3 in yeast) and its heterodimeric receptor in the ER-membrane
(WRB/CAML) (Get1/Get2 in yeast), which can act as signal peptide recognition proteins in
post-translational ER-targeting to the Sec61 complex [102]. Notably, TA-membrane proteins,
such as Sec61β, may also be targeted to the membrane via the same three pathways as
small presecretory proteins [100]. In fact, the TRC- pathway has its primary role in both
targeting TA-membrane proteins to the ER membrane and facilitating their membrane
integration [106–113]. It remains to be seen whether or not the SND-pathway also has an
additional stand-alone membrane protein insertase activity.
2.5.3. Structural Considerations
We note that a permanent association of ribosome-associated Sec61 complexes with
TRAP and OST was confirmed in the three-dimensional (3D) reconstructions after CET
of native translocons in ER membrane vesicles, derived from canine pancreas or various
human cells and even intact cells (Figure 1b,c) [53,54,56,129]. Interestingly, all ribosome-
associated Sec61 complexes were routinely found to be associated with TRAP, irrespective
of the cellular origin of the native complexes. Mammalian TRAP is a heterotetrameric
membrane protein complex, with three subunits (α, β, δ) predicted to comprise one TMH
plus one lumenal domain each, while TRAPγ likely comprises a bundle of four TMHs
plus a central cytosolic domain (Figure 5a) [56,161]. This ensemble of TMHs appears
to be flanking both Sec61γ and the carboxy-terminal half of Sec61α, and the cytosolic
domain interacts with the ribosome via ribosomal protein eL38 and a short RNA expansion
segment. Significantly, the heterotrimeric ER-lumenal segment of TRAP reaches across
the central Sec61 channel where the δ-subunit contacts OST and the α - and β -subunits
contact ER lumenal loop 5 in the hinge region between the amino- and carboxy-terminal
halves of Sec61α. In this position, the ER lumenal domain of TRAP may be able to act in
a chaperone-like fashion on the conformational state of Sec61α or as a molecular ratchet
on incoming precursor polypeptides into the ER lumen or both, in possible analogy to
BiP (see below). We note that various algorithms predict a beta sandwich fold for the ER
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lumenal domains of TRAP’s α- and β- subunits and that TRAPα was also characterized as
Ca2+-binding protein [158].
As discussed before, the Sec61 complex imports polypeptides either co-translationally
or post-translationally. Structural data on the organization of the post-translationally
acting mammalian Sec61 complex are currently missing. However, recent studies high-
lighted the architecture of the detergent solubilized, unoccupied as well as active post-
translational translocon from yeast by cryo-EM [176–179]. In yeast, the fully assembled
post-translational translocon represents a heptameric protein ensemble, the SEC complex.
In the SEC complex the heterotrimeric Sec61 complex is associated with the heterote-
trameric Sec62/63/Sec71/Sec72 complex. These data provided first insights into how
the SEC complex is arranged to allow priming and gating of the Sec61 complex and sup-
port transport of post-translationally transported precursor polypeptides. Most striking
was the extensive interaction between Sec63 and the Sec61 complex including contacts
in their cytosolic, membrane and luminal domains. Specifically, the cytosolic Brl domain
of Sec63 interacts with loops 6 and 8 of Sec61α, which form the ribosome docking site in
co-translational transport. Interestingly, as predicted for the interaction of the TRAPα/β
subunits with the Sec61 complex, the Brl domain of Sec63 shows a canonical beta-sandwich
fold for an antigen-antibody-like binding to loop 6. In the membrane, Sec63 (TMH 3)
contacts all three subunits of the Sec61 complex in the hinge region opposite to the lateral
gate including TMHs 5 and 1 of Sec61α as well the membrane anchors of Sec61β and
Sec61γ. In addition, the short luminal amino-terminus of Sec63 appears to intercalate on
the luminal side of the channel between the Sec61α hinge loop 5 and Sec61γ. Therefore,
binding of the Sec62/63 complex to the Sec61 complex was proposed to induce a fully open
channel that readily accommodates even weak SPs [180]. In the substrate-occupied SEC
complex the SP in transit was additionally flanked by the two Sec62 TMHs [178]. Thus,
while Sec63 seems to assist opening of the Sec61 complex from a position opposite of the
lateral gate, the Sec62 protein resides close to the lateral gate possibly welcoming the SP to
the hydrophobic environment of the membrane.
However, this scenario unlikely reflects the complete picture in human cells, since
the human Sec62/Sec63 complex was found to be involved in co-translational transport
of certain precursor polypeptides (pre-prion protein and pre-ERj3) and to be strictly BiP-
dependent. Briefly, in the case of pre-ERj3 deletion of the carboxy-terminal cluster of
positive charges in Sec63, the Sec62 interaction site, and mutation of the HPD-motif in the
J-domain of Sec63, the BiP interaction site, resulted in reduced import in HeLa cells, as had
been observed for post-translational import of preproapelin (Figure 5b). In comparison
to its yeast ortholog, the mammalian Sec62 protein experienced a gain of function and,
therefore, is able to interact with the ribosome near the ribosomal exit tunnel and to support,
in collaboration with Sec63 and BiP, the co-translational transport of the precursors of ERj3
and prion protein [143,148,156]. In addition, the BiP binding site in Sec61α was character-
ized as a di-tyrosine motif-containing mini-helix in ER luminal loop 7 (Figure 5b) [69,102].
Interestingly, homozygous mutation of tyrosine 344 to histidine in this loop 7 is linked
to Diabetes mellitus in mice (see below) and compromises ER co- and post-translational
import of Sec63- plus BiP-dependent precursor polypeptides, such as preproapelin and
pre-ERj3, when introduced into HeLa cells (as does the Y343H mutation). Notably, in vitro
reconstitutions demonstrated that the yeast SEC complex needs support from the Hsp70
chaperone of the ER lumen, Kar2p or BiP, for efficient post-translational transport [181–184].
This idea was subsequently dismissed on the basis of a model translocation reaction that
allowed precursor movement through the yeast Sec61 complex in detergent solution. We
propose that the BiP-dependent Sec61 channel gating may have been facilitated by the
detergent in this artificial translocation system.
3. Gating of the Sec61 Channel by BiP
The Hsp70-type molecular chaperone immunoglobulin heavy chain binding protein
or BiP, which was discovered by I. Haas, also goes through a cycle of open and closed
Cells 2021, 10, 1036 17 of 47
conformation [82,185–196]. However, in this case the description refers to the state of the
substrate-binding domain (SBD). It also involves allosteric effectors in its conformational
changes and, in contrast to Sec61, the hydrolysis of ATP. It does not only support Sec61
channel opening for ER protein import [69,78,102,197,198], but also can bind to and act
on the incoming precursor polypeptide as a molecular ratchet [83]. Thus, typical for an
Hsp70, the ATP- and Ca2+-dependent BiP modulates the conformation of a folded protein
complex, the Sec61 channel, plus interacts with a more or less unfolded polypeptide chain
as it emerges from the Sec61 channel, thereby vectorizing the transport process. These two
kinds of substrates (folded and unfolded substrates) have previously also been observed
for various other Hsp70s, such as sigma factor 32 in the bacterial cytosol and clathrin
triscelions in the cytosol of human cells. Also typical for an Hsp70, both BiP activities
involve an ATPase cycle, where the chaperone goes through states of substrate trapping in
its ADP-bound state and substrate release in its ATP-bound state (Figure 5b). Furthermore,
these activities involve JDPs, termed ERj- or ERdj-proteins, which stimulate the hydrolysis
of BiP-bound ATP [84,199], and NEFs [200–206], which stimulate the exchange of ADP
for ATP, thereby affecting BiP conformations allosterically [193,194]. Following the same
principles and interactions, BiP also plays a central role in folding and assembly of newly-
imported polypeptides, such as heavy and light chains of immunoglobulins in plasma cells
of the immune system [85,185,186], and supports efficient Sec61 channel closing to preserve
Ca2+ homeostasis [69,207]. In addition, BiP is a key player in various Ca2+-dependent
and -independent signal transduction pathways, which report on ER energy homeostasis
and proteostasis, respectively, and can first increase ATP/ADP exchange between ER and
cytosol, next increase the folding- and ERAD-capacity via UPR and, at last, switch to
apoptosis under conditions of ever increasing protein mis-folding or ER stress [35–44,208].
3.1. Structure and Dynamics of BiP
There are two Hsp70-type chaperones in the human ER (BiP and Grp170) but, more
accurately, Grp170 is a Hsp110 protein family member [78,82,201–204]. Hsp70-type molec-
ular chaperones, such as BiP, bind reversibly to substrate polypeptides via their carboxy-
terminal substrate-binding domains (SBDs) (Figure 5b). Upon ATP hydrolysis the carboxy-
terminal extension of the SDB, termed the lid domain, traps the substrate. Typically, BiP
substrates are hydrophobic oligopeptides of loosely- or un-folded polypeptides. Bind-
ing of a substrate to the SBD inhibits unproductive interactions of the polypeptide and,
thereby, favors productive folding and assembly, which occur concomitantly with release
from BiP. In addition, BiP can also regulate the activities of folded polypeptides, i.e., in-
duce conformational switching of a substrate (here, Sec61α). This binding and release of
substrates by BiP are facilitated by interaction of its carboxy-terminal SBD and its amino-
terminal nucleotide-binding domain (NBD), which are connected via the linker region.
NBD-conformation and BiP’s ATPase cycle are modulated by different allosteric effec-
tors [184–187]. The ATP-bound state of BiP has a low affinity for substrates. In contrast,
the ADP-bound state has a high substrate affinity. ERjs stimulate the ATPase activity of BiP
and favor substrate trapping. NEFs of the ER lumen stimulate the exchange of ADP for
ATP and induce substrate release.
Nine different ERjs reside in the human ER (Table 1) [79–81,130,145–147,209–234]. As
the name infers, ERjs are characterized by individual J-domains, which allow interaction
with BiP via the bottom of its NBD and, to do so, contain four α-helices (helices I–IV) with
a loop region containing a highly conserved tripeptide of histidine, proline, and aspartic
acid (HPD motif) located between helices II and III. They can be divided into membrane
proteins with a lumenal J-domain and into bona fide lumenal proteins (Figure 5b). Only
ERj3 through ERj6 appear to be involved in protein folding under physiological as well
as ER stress conditions and in ERAD. The other ERjs play more specialized roles in ER
protein import (Sec63/ERj2 and ERj1) [79–81,102,143,145–147,151] or ER-phagy (ERj8) [234].
Thus, there is redundancy also at the level of the ERjs, which may explain the non-lethal
phenotype of loss of Sec63 function that is associated with polycystic liver disease (see
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below). Last but not least, Sec63 [102,143,155] and ERj3 together with ERj6 [131] act as BiP
co-chaperones in facilitating conformational changes and, therefore, regulation of the Sec61
complex, which will be discussed in detail in the two following sections.
Grp170 does not only act as a Hsp70-type chaperone, it also acts as one of the NEFs
for BiP [201–204]. There is another functional homolog to bacterial GrpE in the ER lumen
(termed Sil1 or BAP) [200,204], i.e., there is redundancy also at the level of the NEFs,
which may explain the non-lethal phenotype of loss of Sil1 function that is associated
with the neurodegenerative disease, Marinesco–Sjögren syndrome (see below and Table 1).
The structures of the two cytosolic paralogs of the two ER-resident NEFs were solved
and revealed distinct interacting surfaces with the top of the amino-terminal nucleotide-
binding domain (NBD) of the Hsp70 [205,206]. Thus, the NEF binding sites on the Hsp70
are different from the J-domain binding site.
3.2. BiP and Sec62 as Allosteric Effectors of the Sec61 Complex for Channel Closing
The human ER represents the major Ca2+ storage compartment in nucleated cells and
allows the controlled release of Ca2+ from the ER upon hormone stimulation of a resting cell,
e.g., via IP3- or ryanodine receptors [5–13]. Subsequently, Ca2+ is pumped back into the ER
by SERCA to re-establish the steep and crucial ER to cytosol Ca2+ gradient [8]. In addition,
this gradient is constantly challenged by the so-called passive Ca2+ efflux from the ER.
Therefore, SERCA has the additional task of counteracting this Ca2+ leakage. Furthermore,
Ca2+ is taken up by mitochondria. In the course of the last fifteen years, several proteins
were linked to ER Ca2+ leakage, including the Sec61 channel [60–69]. Therefore, the Sec61
channel gating is tightly controlled (Figures 2 and 5).
Originally, sophisticated biophysical measurements on ER-derived membranes estab-
lished that closing of the aqueous Sec61 channel involves BiP and an unidentified JDP to
preserve the ER membrane permeability barrier [197,198,207]. Subsequently, single-channel
recordings from planar lipid bilayers characterized the Sec61 complex as a highly dynamic
aqueous channel that is transiently opened by SPs and permeable to Ca2+ after completion
of protein import [61]. The same experimental strategy showed that the Sec61 channel
closes either spontaneously or as induced by binding of BiP or Ca2+-CaM [61,69,235]. The
fact that BiP is involved in closing the Sec61 channel was confirmed at the cellular level
by combination of siRNA-mediated gene silencing or pharmacological manipulation and
live cell Ca2+ imaging [69]. In addition, cytosolic Ca2+-CaM was shown under similar
conditions to contribute to Sec61 channel closing via an unrelated mechanism after Ca2+
has started to leak from the ER [68]. During the last ten years, additional siRNA-mediated
gene silencing and live cell Ca2+ imaging experiments characterized the pair and, possibly,
heterodimeric complex of ERj3 and ERj6 as specific co-chaperones of BiP and the putative
EF hand- and Ca2+- binding protein Sec62 as a co-factor of CaM in Sec61 channel clo-
sure (Figures 2 and 5b) [131,236]. The idea that a heterodimeric co-chaperone complex is
involved was based on the observation that depletion of ERj6 resulted in a twofold overpro-
duction of ERj3 but the increased ERj3 level did not compensate the decreased ERj6 level in
limiting Ca2+ leakage. The binding site of BiP was identified as the above-mentioned di-
tyrosine motif–containing mini-helix within ER lumenal loop 7 of the Sec61α [69] and was
shown to be relevant to the described mechanisms in cellulo by mutagenesis studies. Again,
the idea is that binding of BiP to loop 7 of Sec61α provides binding energy for shifting the
dynamic equilibrium of the Sec61 channel to the closed state. In case of inefficient channel
closure in intact cells, Ca2+ starts to leak from the ER into the cytosol and binds calmodulin,
and Ca2+-CaM is recruited to the IQ motif in the Sec61α -subunit [68] (Figures 2 and 5b).
Once again, the involved binding energy favors channel closure. Apparently, binding of
Ca2+-CaM is supported by Sec62, which may bind Ca2+ because of its putative EF hand
within its cytosolic carboxy-terminal domain [236]. Next, the Sec61 channel is closed,
and Ca2+ leakage subsides. SERCA pumps Ca2+ back into the ER, CaM and Sec62 return
to the Ca2+-free forms, and the next protein import cycle can be initiated. When these
mechanisms fail, however, the passive Ca2+ efflux of the ER membrane might actually
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represent part of a signaling pathway reporting about protein homeostasis and folding
capacity within the ER lumen and, eventually leading to apoptosis.
4. Sec61-Channelopathies
As outlined above, the Sec61 channel of the human ER membrane and its allosteric
effectors (TRAP, Sec62, Sec63, and BiP) plus BiP´s co-chaperones and NEFs play central
roles in extra- and intra-cellular proteostasis as well as in intracellular Ca2+-homeostasis.
Therefore, the term Sec61-channelopathies was coined for diseases, which are the result
of toxin-driven or hereditary defects in one of the three Sec61 subunits themselves or
in one of the many allosteric effectors of the Sec61 channel (Figure 6) [86]. In general,
genetically-determined defects can affect a single or both alleles coding for a certain
component and are termed heterozygous or homozygous; heterozygous mutations can
result in haploinsufficiency, where the product of the wild type allele cannot compensate
the loss of function of the mutated one, or in a dominant negative effect of the product of
the mutated allele. Bacterial and fungal toxins can have similar effects as mutations [237].
On the other hand, some components of the interaction network of our interest here
appear to have overlapping functions and, therefore, may be partially able to substitute
for each other. In addition, some of the components were found to be overproduced in
various types of tumor diseases, suggesting that overproduction and gain-of-function of
a component can cause or support a disease state, too. Next, we summarize the current
knowledge about these diseases, knowing the basic medical principle that “he who has
fleas can also have lice” or, at the molecular level, that a certain disease may be the result of
simultaneous lack of one function of the component and dominant negative effect of one of
its additional functions.
Figure 6. Hereditary and acquired diseases that are linked to the Sec61 complex and its allosteric effectors. The figure
highlights various disease phenotypes, which are discussed in the text. Proteins affected in human hereditary diseases
are indicated in red, protein targets of toxin-determined human diseases in blue, over-produced proteins in human tumor
diseases in green (see below) and a genetically-determined variant causing murine Diabetes mellitus in grey. The arrows
point upwards for increased activity of the indicated component and downwards for decreased activity. ADPKD, autosomal
dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; ADSCN, autosomal dominant
severe congenital neutropenia; ADTKD, autosomal dominant tubulo-interstitial kidney disease; CDG, congenital disorder
of glycosylation; CVID, common variable immunodeficiency; GBM, glioblastoma multiforme; HUS, hemolytic uremic
syndrome; MSS, Marinesco–Sjögren syndrome; RCC, renal cell carcinoma.
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It is noteworthy in the context of Sec61-channelopathies that endosome-resident Sec61
complexes were shown to be involved in antigen transport from endosomes into the
cytosol for cross-presentation to CD8+ T cells [238]. In the so-called endosome to cytosol
pathway of cross-presentation, antigens are exported from endosomes into the cytosol by
endosome-resident Sec61 channels and degraded by the proteasome, in possible analogy
to Sec61-dependent ERAD. Therefore, this moonlighting function of the Sec61 channel
has always to be considered in Sec61-related diseases, as may equally be true for possible
specialized functions of Sec61 channels in ERAD.
4.1. Bacterial and Fungal Toxins That Target the Sec61 Channel
During the last ten years an ever-growing number of small molecule Sec61 channel
inhibitors was discovered in bacteria and fungi that are best discussed in light of the energet-
ics and kinetics of Sec61 channel gating (Figures 2 and 3) [239–255]. Some of these bacterial
and fungal products are synthesized by pathogenic organisms and toxic to humans (Table 2,
Figure 6). Mycolcatone from Mycobacterium ulcerans is central to the etiology of Buruli
ulcer [242,245]. In general, these small molecules affect ER protein import at the level of
the Sec61 channel in a either precursor-specific or non-selective manner. According to the
kinetic point of view on Sec61 channel gating, inhibitor selectivity is based on the distinct
efficiencies of different amino-terminal SPs and TMHs in reducing the activation energy
for Sec61 channel opening and the common principle that the bound inhibitors increase
the energy barrier for opening of the Sec61 channel. The first-described and precursor-
selective class of such inhibitors were the cyclic heptadepsipeptides, i.e., the fungal product
HUN-7293 and its synthetic relatives CAM749 and Cotransins (e.g., CT8) [239,240,243].
Subsequently, the structurally unrelated compounds Apratoxin A, Mycolactone, Coibamide
A and Impomoeassin F were characterized as Sec61 effectors and shown to have selec-
tive (Mycolactone) or non-selective (Apratoxin A, Coibamide A, Ipomoeassin F) effects
on ER protein import by interaction with the Sec61 channel [244–249,251,253]. Although
the different bindings sites of these small molecules within the Sec61 channel have been
characterized by the selection of resistant Sec61α variants and cryo-EM [243,249,251,252],
respectively, the exact mechanisms of these compounds is an open question. In first at-
tempts to address this puzzle, it was asked whether or not the selectivity of some of the
small molecules correlates with the dependence of some precursors on allosteric Sec61
channel effectors and whether or not the inhibitory compounds affect cellular Ca2+ home-
ostasis. With respect to the first question it was observed in two independent studies that
the import of the BiP- and Sec63-dependent precursors of proapelin and ERj3, respectively,
into the human ER is sensitive to CAM741 [102,143], i.e., that the effect may indeed be
related to SP strength. With respect to the second question the synthetic non-selective Sec61
inhibitor Eeyarestatin 24 (ES24) was found in human cells to trap the Sec61 channel in
a partially open state, which allowed the passage of Ca2+ but not of precursor polypep-
tides, was termed “foot in the door” and may be identical with the primed state of the
channel [241,250]. As a result, the compound induced Ca2+-dependent apoptosis. Recently,
similar phenotypes were observed for Mycolactone (T. Pick, R. Simmonds, A. Cavalié,
personal communication). Thus at least some of the Sec61 inhibitors have a dual effect on
the channel, decrease of ER protein import and increase of Ca2+ leakage, a clear case of “he
who has fleas can also have lice”. These first mechanistic experiments are all consistent with
the kinetic view on Sec61 channel gating but, obviously, have to be extended to additional
Sec61 inhibitors in future experiments.
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Table 2. Sec61 channel inhibitors.
Inhibitor Binding Site in Sec61α Effect Linked Disease(s)
Apratoxin A T86 (TMH2),Y131 (TMH5) non-selective
CAM741 selective inhibition
Coibamide A non-selective
Cotransin CT8 R66 (loop 1), G80 (TMH2),S82 (loop 1), M136 (TMH3) selective inhibition
Eeyarestatin ES24 non-selectiveCa2+ leak inducing




Mycolactone R66 (loop 1),S82 (loop 1)
selective inhibition
Ca2+ leak inducing Buruli ulcer
Notably in this context, the Sec61 channel is also affected by a bacterial protein toxin,
Pseudomonas aeruginosa Exotoxin A, which enters human cells by endocytosis and retrograde
transport and inhibits ER export of immunogenic peptides as well as export of antigens
from endosomes in cross-presentation. Apparently, the exotoxin even induces recruitment
of Sec61 complexes to endosomes. Therefore, the pathogenic bacterium compromises the
immune system of infected humans and can cause pneumonia or sepsis [238,254]. Exotoxin
A binds near the Ca2+-calmodulin binding site to the amino-terminal tail of Sec61α and
arrests the channel in the closed state, which does not even allow the passage of Ca2+ [255].
4.2. Mutated Variants of the Sec61 Channel
The archetype of genetically-determined Sec61-channelopathies in humans are diseases
with mutations in one or both alleles of one of the three ubiquitously expressed SEC61 genes
that have functional consequences in Sec61 channel gating (Table 3) (Figures 1d and 6) [86].
Mammalian cells, which are highly active in protein secretion, termed professional secre-
tory cells, may be particularly sensitive towards problems in Sec61 channel closure and,
therefore, constantly on the verge to apoptosis. This has recently been seen in human
patients associated with dominant negative effects in the course of i) autosomal dominant
tubulointerstitial kidney disease (ADTKD) and glomerulocystic kidney disease in kidney
cells with the Sec61α 1V67G- or Sec61α 1T185A-exchanges [256,257], ii) hypogammaglob-
ulinemia or primary antibody deficiency (PAD) in plasma cells with the Sec61α 1V85D
exchange [258], plus iii) autosomal dominant severe congenital neutropenia (ADSCN) in
neutrophils with the Sec61α 1V67G- or Sec61α 1Q92R-exchanges [256,259] and associated
with Diabetes mellitus for the β-cells of the mouse with the homozygous Sec61α1Y344H
exchange [260]. The fact that ERj6 (DNAJC3) is involved in Sec61 channel closure and
that its absence in human patients, too, causes Diabetes mellitus is in perfect line with this
interpretation [261]. However, efficient Sec61 channel closure is clearly not the only prob-
lem in the archetype Sec61-channelopathies; reduced ER protein import due to reduced
levels of functional Sec61 complexes, i.e., haploinsufficiency, certainly also contributes to
the respective disease phenotypes. While the clinical and laboratory features of affected
patients are well characterized, the detailed molecular mechanisms giving rise to the
tissue- and organ-specific defects despite the ubiquitous expression of the SEC61A1 loci
are still unclear.
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Table 3. Human hereditary Sec61 channelopathies and related diseases.
Disease Linked Gene(s) Sec61 Effect MIM
ADPKD DNAJB11 Ca2+ leak induction *
PKD1, PKD2, UMOD
ADPLD ALG8, GANAB, PRKCSH,
SEC61B, SEC63 selective transport inhibition 617004
ADSCN ELANE, JAGN1, SEC61A1 transport inhibition
Ca2+ leak induction
ADTKD HNF1B, MUC1, REN, selective transport inhibition
SEC61A1, UMOD Ca2+ leak induction 617056
CDG ALG8, SSR3, SSR4, OST48, selective transport inhibition
STT3A, STT3B, TUSC3
CVID CD19, CD20, CD21, transport inhibition
CD80, SEC61A1 Ca2+ leak induction
Diabetes DNAJC3, INS Ca2+ leak induction *
MSS SIL1 248800
The proteins, which are coded by the underlined genes, are discussed in detail in this review. ADPKD, autosomal
dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; ADSCN, autosomal
dominant severe congenital neutropenia; ADTKD, autosomal dominant tubulo-interstitial kidney disease; CDG,
congenital disorder of glycosylation; CVID, common variable immunodeficiency; MSS, Marinesco–Sjögren-
Syndrome. *, expected.
4.2.1. Sec61α 1 p.V67G and p.T185A in ADTKD
In three independent families with seven, two and one patient(s), respectively, suffer-
ing from autosomal dominant tubulointerstitial kidney disease (ADTKD) and glomeru-
locystic kidney disease with congenital anemia, respectively, heterozygous SEC61A1
mutations were identified. These are two missense mutations causing the amino acid
substitutions V67G (in the plug helix) and T185A (near the pore ring in TMH 5), respec-
tively [256,257]. The T185A mutation caused ADTKD with a more severe and complex
tubular phenotype. Two individuals in the one family with the V67G variant, however,
also suffered from recurrent cutaneous abscesses requiring hospitalization until the age of
12 years, which was the result of neutropenia and is discussed next. Both variants were
found to be delocalized to the Golgi apparatus after transient expression in HEK293 cells
as well as in a renal biopsy from a patient. Replacement of wildtype Sec61α by either one
of the two variants in Zebrafish embryos induced convolution defects of the pronephric
tubules, which is consistent with tubular atrophy observed in the patients. Furthermore,
immunohistochemical analysis detected the absence of staining for the secretory protein
renin in juxtaglomerular granular cells from a patient with the T185A substitution but,
instead, renin staining in the cytoplasm of tubular cells, representing a phenocopy of
patients with mutations in the REN gene. This renin secretion deficiency may have been
the result of the Sec61 haploinsufficiency and the major cause for the disease phenotype.
Notably, the MUC1, REN and UMOD genes, which code for the precursors of mucin-1
(MIM: 174000), renin (MIM: 613092) and uromodulin (MIM: 191845), respectively were
previously linked to ADTKD [262].
4.2.2. Sec61α 1 p.Q92R and p.V67G in ADSCN
In three patients suffering from autosomal dominant severe congenital neutropenia
(ADSCN) SEC61A1 missense mutations were described for two independent families. The
heterozygous SEC61A1 mutations identified included two missense mutations causing
the amino acid substitutions V67G (in the plug helix) and Q92R (in the lateral gate TMH
2), respectively [256,259]. The patient with the Sec61α V67G variant also suffered from
ADTKD (see above). In contrast, kidneys were morphologically normal in the patient with
the Sec61α Q92R variant and kidney function remained normal. Both mutations were
observed to cause reduced cellular Sec61 levels due to protein instability and dysregulated
Ca2+ homeostasis. When wildtype Sec61α was replaced with either the Sec61α V67G or
the Q92R variant in HeLa cells, Sec61-dependent ER protein import was decreased, while
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TA protein biogenesis was not compromised. In addition, when wildtype Sec61α was
replaced with the Q92R variant in myeloid leukemic HL-60 cells, Ca2+ leakage from the
ER was increased and differentiation to CD11b+CD16+ cells was reduced, suggesting UPR
dysregulation that was confirmed by single-cell analysis of primary bone marrow-derived
myeloid precursors. In addition, in vitro differentiation of primary CD34+ cells pheno-
copied the UPR upregulation and recapitulated the clinical arrest in granulopoiesis. In vitro
modeling of the two mutations suggested a mechanistic pathway of UPR upregulation
and subsequent selective arrest of myeloid precursors. Notably, the ELANE and JAGN1
genes, which code for the precursors of neutrophil elastase or NE (MIM: 202700) and the
tetraspanning membrane protein jagunal homolog 1 (MIM: 616022), respectively, were pre-
viously linked to ADSCN. NE secretion deficiency or JAGN1 deficiency may have resulted
from the Sec61 haploinsufficiency and may have contributed to the disease phenotype.
Taken together with the observed increased Ca2+ leakage, the two mutated Sec61 channels
represent additional cases of “he who has fleas can also have lice”.
4.2.3. Sec61α 1 p.V85D and p.E381* in CVID
In two families with several patients suffering from early-onset, severe, recurrent
bacterial infections in the respiratory tract and normal B- and T-cell subpopulations in
the peripheral blood but immunoglobulin deficiencies involving IgM, IgG, and IgA were
diagnosed [258]. Hence the diagnosis was primary antibody deficiency or PAD or, specif-
ically, common variable immunodeficiency or CVID. After initiating immunoglobulin
substitution therapy the patients have benefitted from a significant decrease in both num-
ber and severity of infections. Notably, clinical laboratory values that were found to be
altered in patients with SEC61A1-linked ADTKD were normal in SEC61A1-linked CVID
patients. In vitro stimulation of B cells from these patients showed a deficiency to develop
and proliferate into plasma cell clones. The heterozygous SEC61A1 mutations identified
included the missense mutation V85D (i.e., the pore ring- and hydrophobic patch-residue
in TMH 2) as well as one nonsense mutation introducing a premature stop at E381* (TMH
8), i.e., a truncated variant. When wildtype Sec61α was replaced with the Sec61α V85D
variant in HeLa cells, Ca2+ leakage from the ER was increased (possibly due to a more
polar pore ring) and Sec61-dependent ER protein import was decreased (possibly due to
a less hydrophobic patch), while TA protein biogenesis was not compromised. Thus, the
heterozygous CVID-linked missense variant can be expected to behave in a similar manner
in patient cells, i.e., to show a reduced capacity for ER protein import and an increased
Ca2+ efflux from the ER; the haploinsufficiency can also be excepted from the truncated
E381* variant. Indeed, the immunoglobulin secretion capacity of plasma cells from both
types of patients was reduced. Furthermore, in various multiple myeloma cell lines it was
observed that Sec61α V85D over-production selectively impairs plasma cell lines and the
patients did not suffer from deficiencies in other plasma proteins. In addition, in the same
plasma cell lines the levels of the UPR sensors IRE1 and PERK were increased and the
apoptosis-inducing CHOP was activated. Intriguingly, mimicking haploinsufficiency by
reduction of the Sec61 levels in the plasma cell lines via siRNA treatment phenocopied
over-production of the V85D variant. Thus, even Sec61 haploinsufficiency is not easily
tolerated by plasma cell lines. Taken together, Sec61α1 p.V85D and p.E381* apparently
cause CVID because of unresolvable ER stress in the course of differentiation of B cells to
plasma cells during a bacterial infection. Since the dominant negative effect of the Sec61α
V85D variant is stronger than the truncation, the patients with the missense mutation suffer
from a fully penetrant CVID, while the single available patient with the truncation may
show transient episodes of hypogammaglobinemia.
4.2.4. Sec61α1 p.Y344H in Mice in Diabetes mellitus
A murine model for Diabetes mellitus has indicated that a point mutation in the ER
lumenal loop 7 of murine Sec61α leads to a partially deficient Sec61 complex and to β-cell
death and diabetes [260]. Interestingly, insulin secretion per se was not compromised
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by the mutation. However, when protein levels of ERj3 were analyzed in pancreas- and
liver-tissue from homozygous Sec61α+/+ heterozygous Sec61α+/Y344 and homozygous
Sec61αY344H/Y344H mice the presence of the mutated Sec61α was found to cause reduced
ERj3 levels in both organs [143]. Thus, the BiP-dependence of ERj3 import into the mam-
malian ER and its action via Sec61α loop 7-interaction were confirmed in different tissues
of adult mice. When wildtype Sec61α was replaced with the corresponding mutant Sec61α
Y344H in HeLa cells, Ca2+ leakage from the ER was increased and was no longer affected
by manipulation of the BiP concentration [69]. Therefore, it was suggested that failure
of BiP to facilitate Sec61 channel closure in the homozygous SEC61A1Y344H mouse con-
tributes to apoptosis of cells with high secretory activity, such as pancreatic β-cells. It is
interesting to mention that various other mutations and knock-outs of resident ER proteins
can cause diabetes in mice, such as deletion of BiP´s Hsp40-type co-chaperones ERj4 and
ERj6 [222,225,233], or of the BiP-interacting protein PKR-like kinase (PERK) [263]. However,
diabetes can also be caused in man and mice by mutations in genes coding for non-ER
proteins, such as the insulin gene [88].
5. Diseases That Are Related to Allosteric Effectors of the Sec61 Channel
5.1. Loss of TRAP Function in Congenital Disorders of Glycosylation (CDG)
Congenital disorders of glycosylation (CDG) are typically autosomal recessive dis-
eases, which are characterized by altered protein or lipid glycosylation and, as a result,
neurological abnormalities. Various genes have been linked to the disease, most notably
and not surprisingly several genes, which code for subunits of oligosaccharyltransferease
that catalyzes the first step of N-glycosylation in glycoprotein synthesis (Table 1). Typically,
the patients are first identified by the characterization of carbohydrate-deficient plasma
proteins, such as transferrin. Recently, mutations in the human TRAPγ and TRAPδ sub-
units (SSR3 and SSR4, respectively) were found to result in loss of TRAP and congenital
disorders of glycosylation (CDG) [56,143,264,265], suggesting that TRAP plays a direct or
indirect role in the biogenesis of N-glycosylated proteins (MIM 300090 and 606213).
As described above, the combination of siRNA mediated depletion of a certain trans-
port component from human cells with subsequent cellular protein abundance analy-
sis identified the precursors of N-glycosylated as well as unglycosylated secretory and
membrane proteins as TRAP substrates and characterized their SPs with above-average
glycine-plus-proline content and below-average hydrophobicity as distinguishing for
TRAP dependence [143]. Furthermore, control fibroblasts and three CDG patient fibrob-
lasts with TRAP-deficiency were subjected to label-free quantitative proteomic analysis
plus differential protein abundance analysis and the data were analyzed for negatively
affected proteins, i.e., potential TRAP substrates. The proteomic analysis confirmed the
almost complete absence of all TRAP complex subunits in fibroblasts from CDG patients
with mutations in the TRAPG or TRAPD genes and the absence of the OST subunit TUSC3.
Furthermore, the analysis of these chronically TRAP-depleted cells partially confirmed
that the glycine-proline-content of SP plays an important role for TRAP dependence of
precursor polypeptides in ER protein import. Thus, TRAP plays a precursor specific role in
ER protein import, including precursors of N-glycoproteins and membrane proteins.
Although not only glycoproteins were affected by TRAP-depletion in HeLa cells
and human CDG patient fibroblasts, the quantitative proteomic results confirmed the
N-glycosylation deficiency associated with TRAP deficiency. They suggested that this may
result directly from the depletion of TRAP, or from its secondary effects on OST or from
a defect in a potential supportive role of TRAP in N-glycosylation, which would not be
unexpected in light of the direct interaction of TRAP and OST seen in CET (Figure 1c). In
any case, CDG as a result of TRAP deficiency is a precursor specific ER protein import
defect. The question why this defect is not lethal may best be explained with the kinetic
model for Sec61 channel gating (Figure 3), the allosteric effector affects the kinetic but not
the equilibrium of the reaction. Furthermore, Sec63 may be able to compensate loss of
TRAP function for some precursor polypeptides.
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5.2. Sec63 and Sec61β in Autosomal Dominant Polycystic Liver Disease (ADPCLD)
Various human organs can develop multiple cysts, i.e., fluid-filled sacs, which are, typ-
ically formed by a certain cell type [266–268]. The classical example of this type of human
inherited disease is autosomal polycystic kidney disease (ADPKD; MIM 173900) [266,267].
It is characterized by multiple renal cysts as well as additional extra-renal manifestations,
such as cysts in the liver bile ducts. Mutations in two genes were linked to ADPKD: PKD1
codes for polycystin 1 (PC1), a plasma membrane resident receptor, and PKD2 codes for
polycystin 2 (PC2) or TRPP2, a member of the transient receptor potential protein family
that resides in the ER and the plasma membrane. Some research on ADPKD suggested
PKD mutations result in problems in downstream signaling- as well as cell adhesion com-
ponents, most notably ß-catenin, and that these problems cause alterations in planar cell
polarity and tubular morphogenesis that, eventually, result in cyst formation.
Autosomal dominant polycystic liver disease (ADPLD or PCLD, MIM 174050) is
an ADPKD-related human disorder, characterized by the progressive development of
biliary epithelial liver cysts (Figure 7) [269–273]. This inherited disease usually remains
asymptomatic at young ages and manifests between the ages of 40 and 60 years. Liver
function is usually preserved. Although ADPLD patients hardly ever suffer from other
polycystic organ disorders, the etiologies of ADPKD and ADPLD may be related. On the
genetic level, ADPLD is heterogeneous involving at least five different genes, which code
for proteins that are involved in the biogenesis of secretory and plasma membrane proteins
(Table 1) [270–273]: (i) ALG8, which codes for alpha-1,3-glucosyltransferase that is involved
in the dolichol-linked oligosaccharide precursor for N-linked glycosylation; (ii and iii)
GANAB and PRKCSH, encoding the α- and β-subunit, respectively, of glucosidase II, which
is a resident protein of the ER lumen and involved in the folding of glycoproteins [268],
(iv and v) SEC61B and SEC63, which code for the β-subunit of the Sec61 complex and
Sec63, respectively, that reside in the ER membrane and are involved in ER protein import.
A loss of function was postulated for all cases described. Although no mechanism has been
firmly established for ADPLD, the etiology of the disease is best explained by a two-hit
mechanism. Accordingly, patients with one inherited mutant allele and one wild type allele
may at some point lose the function of the second allele in a few cholangiocytes through
somatic mutation. Next, the progeny of these cells develop into cysts. The mechanism of
cyst development is still unclear. The most likely scenario would be that all five proteins
are essential for the biogenesis of a single protein or a set of proteins that are involved in
the control of biliary cell polarity or cell adhesion, and in the absence of their functions,
these proteins do not reach their functional location. This could result in alterations in
planar cell polarity and morphogenesis. This view was confirmed and it was concluded
that the secondary lack of PC1 and PC2 results in disrupted cell adhesion and, therefore,
cyst formation [155,272]. Notably, ALG8 was also linked to CDG (see above). Depending
on the severity of the disease, the treatment options for this disease extend from aspiration
of cysts as guided by ultrasound or computer tomography, to liver resection, all the way to
liver transplantation (Figure 7).
Following the depletion of Sec63 from HeLa cells, the quantitative proteomic results
confirmed a precursor specific ER protein import defect, which affected the biogenesis
of soluble and membrane proteins irrespectively of whether they were N-glycosylated
or not. An additional Sec63 function has to be considered. Sec63 also plays a role as
nucleoredoxin interactor and, therefore, may be involved in the Wnt/ β-catenin signaling
pathway, which also has been shown to play a role in planar cell polarity. However, the
fact that three additional proteins, involved in protein biogenesis at the ER but involved
in entirely different aspects of this process, cause the same disease argues strongly for the
interpretation, that the ER import defect caused by Sec63 deficiency is responsible for the
disease. The question why this defect is not lethal may best be explained with the kinetic
model for Sec61 channel gating (Figure 3), but may also have something to do with ERj1,
which may have overlapping functions with Sec63.
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Figure 7. Autosomal dominant polycystic liver disease. Photographs of various ADPLD patients are shown in (a–c). (d)
represents a computer tomogram of another patient.
5.3. BiP and Its Co-Chaperones and NEFs in Diabetes and Neurological Disorders
5.3.1. BiP Deficiency in Hemolytic Uremic Syndrome (HUS)
Shiga toxigenic Escherichia coli (STEC) strains can cause morbidity and mortality in
infected humans [274]. Some of these pathogens produce amongst various others AB5 toxin
or subtilase AB (SubAB) and are responsible for gastrointestinal diseases, including the
life-threatening haemolytic uraemic syndrome (HUS) (MIM 235400). During an infection,
the bacterial cytotoxin enters human cells by endocytosis and retrograde transport delivers
it to the ER. In the ER, BiP is the major, or possibly the only, target of the catalytic subunit
A, which inactivates BiP by a single reaction of limited proteolysis within the linker region
(Figure 5b). Eventually, all above-outlined BiP functions are lost, and the affected cells die.
Therefore, global loss of BiP function is not compatible with life. This acquired disease is
by definition a chaperonopathy, i.e., the result of a certain chaperone deficiency. Here, it is
mentioned in the context of Sec61 channelopathies for comparison.
5.3.2. Marinesco–Sjögren Syndrome (MSS)
Mutant variants of BiP interaction partners are associated with the manifestation
of neurological diseases [275–305]. In 2005, recessive SIL1 mutations were linked to the
phenotypical manifestation of Marinesco–Sjögren syndrome (MSS; MIM: 248800) (Figure 8),
a rare autosomal recessively inherited multisystemic disorder characterized by a vacuolar
myopathy, congenital or infantile manifesting cataracts and cerebellar atrophy leading
to ataxia (Figure 8b) [276,277]. Intellectual disability occurs in the majority but not in all
patients [280]. Moreover, a vulnerability of the peripheral nervous system in terms of axonal
degeneration was identified. A mouse model of the disease called ‘woozy´ represents a
good phenocopy of the human disease by showing cerebellar atrophy characterized by
a degeneration of Purkinje cells of the vestibulocerebellum leading to ataxia, a vacuolar
myopathy as well as degeneration of peripheral axons (Figure 8c) [278,279,281,284,288].
Ultrastructural investigations of skeletal muscle of man and mouse showed a profound
disintegration of the nuclear envelope characterized by the proliferation of the lamina
fibrosa, a finding which is in line with the enrichment of BiP within the nuclear envelope
in muscle cells (Figure 8a) [275]. Of note, mitochondrial degeneration is also a major
ultrastructural finding in SIL1/Sil1-mutant muscle.
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Figure 8. Marinesco–Sjögren-Syndrome. (a) BiP-enrichment in the nuclear envelope of muscle cells
visualized by co-immunofluorescence on a human quadriceps muscle biopsy from a healthy donor;
left panel highlights co-localization of BiP with KPNB1 (Importin subunit beta-1) within the nuclear
envelope, the middle panel illustrates co-localization of BiP with Matrin-3, the right panel illustrates
a co-localization of BiP with INPP5K. (b) A photograph of a genetically confirmed MSS patient from
Pakistan. (c) Upper figure shows the cerebellum of a 26-weeks old wildtype mouse with regular
appearance and distribution of Purkinje cells immunoreactive for STIM1 (brown labelling: Visualized
by immunohistochemistry). Lower figure shows the cerebellum of a 26-weeks old woozy animal (no
expression of Sil1 as a BiP co-chaperone) with loss of Purkinje cells. Scale bars: 50 µm.
SIL1 encodes the ubiquitously expressed Sil1 or BAP which is also controlled by
ER-stress and induction of the unfolded protein response [287]. Quantitative studies
of BiP, GRP170 and Sil1 in human muscle cells (RCMH) revealed a molecular ratio of
1:0.1:0.001 [286]. Beside the interaction with BiP, a binding to POC1A, a protein linking
centrosomes to Golgi assembly was demonstrated [278]. Notably, pathogenic missense
variants of Sil1 lead to a disruption of the SIL1-POC1A interaction which is in turn as-
sociated with centrosome disintegration [289]. Further morphological and biochemical
studies on an in vitro model (Sil1-depleted HEK293 cells) utilizing electron microscopy
and unbiased proteomic profiling revealed structural changes of the ER including the
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nuclear envelope and mitochondrial degeneration that closely mimic pathological alter-
ations in MSS as well as indicated that proteins involved in cytoskeletal organization,
vesicular transport, mitochondrial function, and neurological processes contribute to Sil1
pathophysiology [285]. Moreover, a particular function of Sil1 for etiopathology of two
neurodegenerative disorders, amyotrophic lateral sclerosis (ALS) and Alzheimer disease
was highlighted, thus declaring the functional Sil1-BiP complex as a modifier for neurode-
generative disorders [282,283,287].
The hypoxia up-regulated protein 1 (HYOU1/Grp170) displays an BiP-independent
chaperone activity but represents another NEF for BiP, too. This raises the question why
loss of functional Sil1 cannot be compensated by increased expression of HYOU1: Previ-
ous studies have shown that over-expression of Grp170 in mice causes severe myopathic
changes of skeletal and cardiac muscle. Thus, forced expression of Grp170 might result
in a worsening of the muscular pathology rather than in an amelioration of the pathol-
ogy. However, focussing on the nervous system in the “woozy” mouse model, Zhao and
co-workers demonstrated that overexpression of HYOU1 prevents ER stress and rescues
neurodegeneration, whereas decreasing expression of HYOU1 exacerbates these pheno-
types [290,291]. Hence, one might assume that different tissues show varying tolerances
against the increased expression of HYOU1.
ERj6/DNAJC3/p58(IPK) is a co-chaperone that promotes ATP hydrolysis by BiP and
is involved in folding, assembly, ERAD and Sec61 gating to the closed state (the latter
together with ERj3). In vivo studies utilizing the “woozy” mouse model revealed that
decrease of ERj6 ameliorates ER stress and neurodegeneration in these animals suggesting
that alterations in the nucleotide exchange reaction of BiP cause ER stress and neurode-
generation in Sil1-deficient neurons [278,279]. In 2014, recessive DNAJC3 mutations were
linked to Diabetes mellitus complicated by multisystemic neurodegeneration including
ataxia, upper-motor-neuron damage, peripheral neuropathy, sensorineural hearing loss,
and cerebral atrophy [261] (MIM: 616192) and a further clinical and molecular genetic
study confirmed the phenotype associated with recessive loss of function mutations within
DNAJC3 [292]. Although precise molecular data unravelling the underlying pathomecha-
nisms are still scarce a recent study points at BIM- and PUMA-dependent activation of the
mitochondrial pathway of apoptosis [292].
Matrin-3 (MATR3) is a highly conserved phosphoprotein resident within the nu-
clear envelope playing a role in transcription. The interaction with other nuclear enve-
lope/matrix proteins moreover suggests a function in the maintenance of the internal
fibrogranular network. A study published in 2014 described an interaction with BiP [294], a
molecular finding which accords with our observed co-localization of both proteins within
the nuclear envelope (see above) as well as the identified dysregulation of MATR3 in the
diseased muscle of “woozy” animals in terms a pathological proliferation of the lamina
fibrosa. Functional data showed that downregulation of BiP triggers the caspase cascade
pathway leading to MATR3 degradation [294].
Inositol 5-phosphatase (INPP5K/SKIP) acts on the inositol 1,4,5-trisphosphate, the
inositol 1,3,4,5-tetrakisphosphate, the phosphatidylinositol 4,5-bisphosphate and the phos-
phatidylinositol 3,4,5-trisphosphate pathway [298]. In agreement with a described interac-
tion with BiP [298], INPP5K localizes in part to the sarcoplasmic/endoplasmic reticulum
where it is preferentially localized in ER tubules and enriched (relative to other ER resident
proteins such as Sec61β), in newly formed tubules [300]. In 2017, recessive INPP5K mu-
tations were linked to congenital muscular dystrophy with cataracts and mild cognitive
impairment [301,302] (MIM: 617404). Like in MSS-patients, muscle pathology in INPP5K-
patients is also characterized by the disruption of the architecture of the nuclear envelope
with proliferation of the lamina fibrosa [302], suggesting common pathomechanisms. Thus,
as for the pathophysiology related to MSS and the Matrin-3 associated phenotypes, also
for INPP5K a defective protein clearance machinery seems to be one of the pathomecha-
nisms contributing to the clinical manifestation of the diseases, especially in terms of the
muscular phenotypes.
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5.3.3. ERj3 in Polycystic Kidney Disease (PKD)
Besides the classical autosomal polycystic kidney disease (ADPKD), which is charac-
terized by multiple cysts and organ enlargement, there is a late-onset form of the disease
(age 60+), which does not result in enlarged kidneys and shows progressive interstitial
fibrosis, i.e., phenotypic overlap with autosomal-dominant tubulointerstitial kidney disease
(ADTKD), which can result from certain SEC61A1 mutations (see above). Recently, this
PKD form was linked to the DNAJB11 gene, which codes for ERj3, a co-chaperone of BiP
that promotes ATP hydrolysis by BiP and is involved in folding, assembly, Sec61 gating to
the closed state and ERAD (Table 1). Specifically, two mutations in the J-domain, p.P54R
(affecting the HPD motif) and p.L77P, two frameshift mutations in the cysteine-rich domain
and one truncation, respectively, were described [306]. In respective null cells of the gene
and in kidney samples from affected individuals the pathogenesis was associated with
secondary defects in PC1, the plasma membrane resident receptor that plays a role in cell
polarity, and uromodulin, one of the most abundant secretory proteins in our body and
the most abundant urinary protein. Mutant variants have previously been linked to the
UMOD gene, which codes for the precursor of uromodulin (MIM: 191845). For the latter
disease it has been suggested that mis-folded mutant variants accumulate in the ER of
thick ascendant limb of the loop of Henle- or TAL-cells and cause progressive cell damage.
Notably, however, ERj3 (DNAJB11) is involved in Sec61 channel closure and its absence in
human patients, too, may cause additional problems in Ca2+-homeostasis.
6. Tumor Diseases That Are Related to the Sec61 Channel
Professional secretory cells with their abundant rough ER appear to be particularly
sensitive to imbalances in the Sec62 to Sec63 ratio, which result in over-efficient Sec61
channel closure at a higher than average ratio and, thus, a proliferative and/or migratory
advantage that can lead to cancer, e.g., seen after over-expression of SEC62 in prostate or
lung cancer. That may be due to the role of Sec62 in maintenance of Ca2+ homeostasis
but may also be related to its role in ER proteostasis, i.e., ER-phagy, or both. Due to poor
vascularization and the resulting hypoxia and glucose starvation, tumor cells are prone to
ER stress and, therefore, UPR [307,308]. In cultured cells, BiP is one of the proteins involved
in protecting cancer cells against ER stress-induced apoptosis [309]. In addition to this
general link between BiP and cancer, some of the above-mentioned directly or indirectly
interacting proteins of BiP have been connected to certain tumors.
Over the past 15 years, increasing evidence suggests a relevant role of SEC61, SEC62,
and SEC63 genes in the development and tumor cell biology of human malignancies
(Figure 9) [310–341]. In 2002, a first publication described frameshift mutations of SEC63
due to microsatellite instability (MSI) in 37.5% of gastric cancers and 48.8% of colorectal
cancers [310]. Similar results were reported in 2005 [311] and in 2013 [324], where MSI
associated SEC63 frameshift mutations were found in 56% of small-bowel cancers in
patients with hereditary non-polyposis colorectal cancer (HNPCC) [311] and in one case of
hepatocellular carcinoma [324].
In recombinant inbred mouse lines showing different basal SEC63 expression levels,
low hepatic expression correlated significantly with a decrease in apoptosis and increased
proliferative activity [324]. Taken together, the aforementioned studies suggest a function
of SEC63 as tumor suppressor gene in gastrointestinal and hepatic cancer, though the
underlying molecular mechanisms largely remain unknown.
For the SEC61 genes increased expression and gene amplification were reported
for gastric cancer, colorectal cancer, alcohol-induced hepatocellular cancer, breast cancer
and glioblastoma [314–317,323,330,336–338]. In glioblastoma multiforme (GBM), Liu et al.
demonstrated a significant correlation of high SEC61G expression with poor prognosis
based on statistical analysis of sequencing data from the Cancer Genome Atlas cohort
(TCGA) and the Chinese Glioma Genome Atlas cohort (CGGA) [337]. Univariate and
multivariate Cox proportional hazards regression verified SEC61G as an independent prog-
nostic factor for prognosis and therapeutic outcome in these cohorts. Gene set enrichment
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analysis (GSEA) and gene set variation analysis (GSVA) suggested a connection to the
Notch pathway as a possible molecular backbone for these observations, though more data
are needed to prove this hypothesis. In view of potential therapeutic implications of these
observations, Sec61 inhibitors including Exotoxin A, Mycolactone, Apratoxin A, Cotransin,
and Eeyarestatin I were identified and proved to sufficiently block the translocation of
precursor proteins as well as Ca2+ leakage through the Sec61 channel [331]. However,
only Exotoxin A has been tested in first clinical studies on human cancer patients so far
and it is not more than speculative if the role of Sec61 in ER protein import and/or Ca2+
homeostasis is responsible for its observed association with the clinical course of human
cancer diseases.
Figure 9. SEC61, SEC62, and SEC63 in human cancer. Overview of genetic changes and altered expression of SEC61,
SEC62, and SEC63 gene in human cancer entities segregated by the tissue of origin (column-wise from top left to bottom
right: Head and neck, lung, liver, kidneys, skin, female genital tract, brain, breast, stomach, intestine, and male genital
tract). Green arrows symbolize functional gain by overexpression/amplification, red arrows symbolize functional loss by
low expression/deletion, mutations are indicated by single-strand DNA break symbols. AFX—atypical fibroxanthoma;
HCC—hepatocellular carcinoma; HNSCC—head and neck squamous cell carcinoma; NSCLC—non-small cell lung cancer;
RCC—renal cell carcinoma.
Highest evidence for a causative role of a protein translocation component in the
development and tumor cell biology of human cancer exists for the ER transmembrane pro-
tein Sec62. In 2006, a first study found SEC62 copy number gains in 7 of 13 prostate cancer
samples as well as elevated Sec62 protein levels in three prostate cancer cell lines [313]. In
the following years, amplification and overexpression of the SEC62 gene was reported for
various other cancer entities, including non-small cell lung cancer [318,320,328], thyroid can-
cer [318,320], hepatocellular cancer [322,340], ovarian cancer [325], breast cancer [325,334],
head and neck squamous cell carcinoma [329,330], cervical cancer [336], vulvar cancer [335],
atypical fibroxanthoma [339], and in larger prostate cancer patient cohorts [319]. When
screening publicly available DNA sequencing data from over 72,000 cancer patients with 55
different tumor entities (cBio Portal for cancer genomics; https://www.cbioportal.org ac-
cessed on 21 April 2021) SEC62 gene alterations are reported for 2595 patients and represent
gene amplifications in the majority of cases (Figure 10a).
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Figure 10. Genetic alterations of the SEC62 gene and impact on overall survival. (a) Alteration frequency for the SEC62 gene
in a total cohort of 72,012 cancer patients based on publicly available DNA sequencing data entities (cBio Portal for cancer
genomics). Results are illustrated only for a subset of patient cohorts with the highest alteration frequency. Red bars indicate
gene amplification, green bars indicate gene mutation, blue bars indicate deep deletions. (b) Overall survival for patients
with (red) and without (blue) alterations in the SEC62 gene independent of alteration type. Censored data are labeled by
crosses. In total, 40,006 patients were included in the survival analysis; 1487 patients showed SEC62 alterations, 38,519
patients showed no SEC62 alterations; median survival with SEC62 alterations: 54.2 months, median survival without
SEC62 alterations: 95.6 months.
However, from a functional point of view only few studies addressed the specific
impact of altered SEC62 expression levels on cancer cell biology. A first step to uncover
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potential associations of SEC62 overexpression with tumor cell biology are correlation
analyses with clinical data. Thereby, Greiner et al. found an association of high SEC62
expression level with higher Gleason Score in prostate cancer [319]. In non-small cell
lung cancer, high Sec62 levels correlated with the occurrence of lymph node metastases
and poor tumor differentiation [320]. Similarly, an association of SEC62 overexpression
with lymphatic metastasis was reported for head and neck squamous cell carcinoma [330]
as well as an association of SEC62 overexpression with distant metastasis in breast can-
cer [334]. These results indicated a potential role of Sec62 in cancer metastasis, which was
strengthened by several functional studies. A significant inhibition of cancer cell migration
by SEC62 gene silencing was reported for prostate cancer cells [318], non-small cell lung
cancer cells [320], thyroid carcinoma cells [320], cervical cancer cells [328], hepatocellu-
lar carcinoma cells [340], and head and neck squamous cell carcinoma cells [330]. On
the contrary, SEC62 overexpression stimulated migration of HEK293, HeLa, Huh-7 and
FaDu cells [236,319,330,340] and induced subcutaneous tumor growth in C.Cg/AnNTac-
Foxn1nu/nu mice, inoculated with SEC62 overexpressing HMLE cells [325]. An influence of
SEC62 expression level on stress tolerance of human cancer cells was suggested by several
studies reporting a higher sensitivity to ER stress induced by CaM inhibitors when SEC62
is expressed at low levels [319,320,328]. Thereby, the regulation of Sec61-mediated Ca2+
efflux through the ER membrane by Sec62 is supposedly the key function for the migration
stimulating effect and improved stress tolerance [328]. However, the broad influence of a
potentially dysregulated ER-phagy in SEC62 overexpressing cancer cells cannot be ruled
out [32].
With regard to a potential prognostic relevance of SEC62 expression, several studies
reported a significant correlation of elevated Sec62 levels with poor patient prognosis
in non-small cell lung cancer [328], breast cancer [334], liver cancer [322], and head and
neck cancer [329,330]. SEC62 expression was also identified as a potentially independent
prognostic factor for early recurrence in postoperative HCC patients [340]. Consistently,
a correlation of SEC62 amplification with overall survival in 40,006 cancer patients (45
different tumor entities) based on publicly available DNA sequencing and clinical data (cBio
Portal for cancer genomics; https://www.cbioportal.org, accessed on 21 April 2021) shows
a highly significant association of SEC62 amplifications with poor prognosis (Figure 10b).
Together, these data strongly indicate a role of SEC62 as a driver oncogene in various
human cancers with a consistent association with poor prognosis, lymph node as well as
distant metastasis and stress tolerance, which turns the Sec62 protein into an attractive
target for anticancer therapy. As Sec62 is hardly accessible for monoclonal antibodies due
to its intracellular location, alternative strategies had to be developed to achieve at least
a functional knock-down. Thereby, based on the role of Sec62 in the regulation of Ca2+
efflux through the Sec61 channel, CaM inhibitors (e.g., Trifluoperazine, TFP) and inhibitors
of SERCA (e.g., Thapsigargin, TG) were investigated as potential therapeutics. Indeed,
CaM inhibitors showed a functional Sec62 knockdown by blocking Ca2+ efflux from the
ER lumen [328] and inhibiting cancer cell migration in cervix and prostate cancer cells with
inhibition of cancer cell proliferation at higher doses [328]. One first in vivo study reported
a significant inhibition of seeding and growth of a subcutaneously injected head and neck
squamous cell carcinoma cell line (FaDu) in BALB/cAnNRj-Foxn1nu/nu mice by single
and combined treatment with TFP and TG [333]. Ongoing in vivo studies focusing on
lymphatic and hematogeneous metastasis have to show if the migration inhibition that was
found for various cancer cell entities in vitro manifests as a clinically relevant phenotype
in a living organism. Within the scope of such therapeutic concepts, an additional benefit
of autophagy inhibitors such as bafilomycin A1 and chloroquine seems to be conceivable
was well, due to the central function of Sec62 in the process of ER-phagy [332].
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